Winston Wong1,2, Maeve A Lowery1,2,3, Michael F Berger4, Yelena Kemel4, Barry Taylor4, Ahmet Zehir4, Preethi Srinivasan4, Chaitanya Bandlamudi5, Joanne Chou6, Marinela Capanu6, Anna Varghese1,2,3, Kenneth H Yu1,2,3, Christine A Iacobuzio-Donahue3,7, Jinru Shia7, David S Klimstra8, William R Jarnagin8, Zsofia K Stadler1,2,3, Eileen M O'Reilly1,2,3. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Weill Cornell Department of Medicine, Weill Cornell Medicine, New York, New York. 3. David M. Rubenstein Center for Pancreatic Research, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Robert and Kate Niehaus Center for Inherited Genomics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Ampullary carcinoma (AC) is a rare gastrointestinal cancer. Pathogenic germline alterations (PGAs) in BRCA2 and potentially targetable somatic alterations (SAs) in ERBB2 and ELF3 have been previously described in AC. Memorial Sloan Kettering Cancer Center has implemented an opt-in strategy for germline testing (GT) and somatic testing (ST) for patients with AC to further evaluate the spectrum of PGAs and SAs. METHODS: Forty-five patients with pathologically confirmed AC prospectively consented with the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) test (410-468 genes). A subset of the cohort (23 of the 45 patients) also consented to GT with MSK-IMPACT (76-88 genes). Germline data for 21 of the remaining 22 patients who had not consented to GT were obtained in a de-identified fashion without clinical correlation. Clinicopathologic features, treatment histories, and survival data for consenting patients were collected and analyzed. RESULTS: Pancreaticobiliary, intestinal, and mixed features of the 2 types were the primary pathologic subtypes of AC identified in this cohort. No difference in median overall survival was found between pathologic subtypes. Eight of 44 patients (18%) were identified as harboring pathogenic mutations in BRCA2, ATM, RAD50, and MUTYH. In addition, this study found a wide spectrum of SAs in genes such as KRAS, MDM2, ERBB2, ELF3, and PIK3CA. Two patients in the cohort underwent SA-targeted therapy, and 1 had a partial radiographic response. CONCLUSIONS: Mutations in multiple somatic and germline genes were identified in this cohort. Significantly, actionable targets were identified in the tumors, and broader testing for PGAs and SAs should be considered for all patients with AC.
BACKGROUND:Ampullary carcinoma (AC) is a rare gastrointestinal cancer. Pathogenic germline alterations (PGAs) in BRCA2 and potentially targetable somatic alterations (SAs) in ERBB2 and ELF3 have been previously described in AC. Memorial Sloan Kettering Cancer Center has implemented an opt-in strategy for germline testing (GT) and somatic testing (ST) for patients with AC to further evaluate the spectrum of PGAs and SAs. METHODS: Forty-five patients with pathologically confirmed AC prospectively consented with the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) test (410-468 genes). A subset of the cohort (23 of the 45 patients) also consented to GT with MSK-IMPACT (76-88 genes). Germline data for 21 of the remaining 22 patients who had not consented to GT were obtained in a de-identified fashion without clinical correlation. Clinicopathologic features, treatment histories, and survival data for consenting patients were collected and analyzed. RESULTS: Pancreaticobiliary, intestinal, and mixed features of the 2 types were the primary pathologic subtypes of AC identified in this cohort. No difference in median overall survival was found between pathologic subtypes. Eight of 44 patients (18%) were identified as harboring pathogenic mutations in BRCA2, ATM, RAD50, and MUTYH. In addition, this study found a wide spectrum of SAs in genes such as KRAS, MDM2, ERBB2, ELF3, and PIK3CA. Two patients in the cohort underwent SA-targeted therapy, and 1 had a partial radiographic response. CONCLUSIONS: Mutations in multiple somatic and germline genes were identified in this cohort. Significantly, actionable targets were identified in the tumors, and broader testing for PGAs and SAs should be considered for all patients with AC.
Authors: David K Chang; Nigel B Jamieson; Amber L Johns; Christopher J Scarlett; Marina Pajic; Angela Chou; Mark Pinese; Jeremy L Humphris; Marc D Jones; Christopher Toon; Adnan M Nagrial; Lorraine A Chantrill; Venessa T Chin; Andreia V Pinho; Ilse Rooman; Mark J Cowley; Jianmin Wu; R Scott Mead; Emily K Colvin; Jaswinder S Samra; Vincenzo Corbo; Claudio Bassi; Massimo Falconi; Rita T Lawlor; Stefano Crippa; Nicola Sperandio; Samantha Bersani; Euan J Dickson; Mohamed A A Mohamed; Karin A Oien; Alan K Foulis; Elizabeth A Musgrove; Robert L Sutherland; James G Kench; C Ross Carter; Anthony J Gill; Aldo Scarpa; Colin J McKay; Andrew V Biankin Journal: J Clin Oncol Date: 2013-02-25 Impact factor: 44.544
Authors: Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly Journal: Clin Cancer Res Date: 2018-01-24 Impact factor: 12.531
Authors: Volkan Adsay; Nobuyuki Ohike; Takuma Tajiri; Grace E Kim; Alyssa Krasinskas; Serdar Balci; Pelin Bagci; Olca Basturk; Sudeshna Bandyopadhyay; Kee-Taek Jang; David A Kooby; Shishir K Maithel; Juan Sarmiento; Charles A Staley; Raul S Gonzalez; So Yeon Kong; Michael Goodman Journal: Am J Surg Pathol Date: 2012-11 Impact factor: 6.394
Authors: Mohammad F Shaikh; William F Morano; John Lee; Elizabeth Gleeson; Blake D Babcock; Josef Michl; Ehsan Sarafraz-Yazdi; Matthew R Pincus; Wilbur B Bowne Journal: Ann Clin Lab Sci Date: 2016-12 Impact factor: 1.256
Authors: Daniel Baumhoer; Inti Zlobec; Luigi Tornillo; Wolfgang Dietmaier; Peter H Wuensch; Arndt Hartmann; Fausto Sessa; Petra Ruemmele; Luigi M Terracciano Journal: Virchows Arch Date: 2008-10-21 Impact factor: 4.064
Authors: Marie-Claude Gingras; Kyle R Covington; David K Chang; Lawrence A Donehower; Anthony J Gill; Michael M Ittmann; Chad J Creighton; Amber L Johns; Eve Shinbrot; Ninad Dewal; William E Fisher; Christian Pilarsky; Robert Grützmann; Michael J Overman; Nigel B Jamieson; George Van Buren; Jennifer Drummond; Kimberly Walker; Oliver A Hampton; Liu Xi; Donna M Muzny; Harsha Doddapaneni; Sandra L Lee; Michelle Bellair; Jianhong Hu; Yi Han; Huyen H Dinh; Mike Dahdouli; Jaswinder S Samra; Peter Bailey; Nicola Waddell; John V Pearson; Ivon Harliwong; Huamin Wang; Daniela Aust; Karin A Oien; Ralph H Hruban; Sally E Hodges; Amy McElhany; Charupong Saengboonmee; Fraser R Duthie; Sean M Grimmond; Andrew V Biankin; David A Wheeler; Richard A Gibbs Journal: Cell Rep Date: 2016-01-21 Impact factor: 9.423
Authors: Eileen M O'Reilly; Jonathan W Lee; Maeve A Lowery; Marinela Capanu; Zsofia K Stadler; Malcolm J Moore; Neesha Dhani; Hedy L Kindler; Hayley Estrella; Hannah Maynard; Talia Golan; Amiel Segal; Erin E Salo-Mullen; Kenneth H Yu; Andrew S Epstein; Michal Segal; Robin Brenner; Richard K Do; Alice P Chen; Laura H Tang; David P Kelsen Journal: Cancer Date: 2018-01-16 Impact factor: 6.860